New drug combo shows promise for Tough-to-Treat lymphomas
NCT ID NCT03259503
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 1 trial tested the safety and best dose of olaparib when added to high-dose chemotherapy for 50 patients with lymphomas that returned or didn't respond to treatment. All patients were scheduled for a stem cell transplant. The goal was to see if the combination could work better than chemotherapy alone, but the main focus was on side effects and dosing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Olaparib (a PARP inhibitor) combined with high-dose chemotherapy (busulfan, gemcitabine, melphalan) and sometimes rituximab
What this could lead to
If successful, this combination could offer a new treatment option for patients with hard-to-treat lymphomas who are undergoing a stem cell transplant.
What could go wrong
This is an early phase 1 trial with only 50 participants, so the main goal was safety and dosing, not effectiveness. The added drugs may increase side effects, and it's unclear if the combination works better than standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States